Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Synchrony Financial (SYF) Price & Performance

ADMA Biologics IncTrade
Synchrony FinancialTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Synchrony Financial — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Synchrony Financial trades at $78.37 (market cap $25.53B). The key difference: Synchrony Financial is far larger — about 11.5× ADMA Biologics Inc's market cap, and Synchrony Financial pays a 1.73% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMASYF
Market Cap
$2.22B$25.53B
Sector
HealthFinancials
52-Week High
$20.38$88.47
52-Week Low
$7.60$63.78
Enterprise Value
$2.29B
Dividend Yield
1.73%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.

Read more on SYF